Compare NEON & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEON | NEUP |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | Sweden | United States |
| Employees | N/A | 8 |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 23.8M |
| IPO Year | 1994 | N/A |
| Metric | NEON | NEUP |
|---|---|---|
| Price | $1.40 | $4.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 99.6K | 52.1K |
| Earning Date | 05-13-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,108,000.00 | N/A |
| Revenue This Year | $72.74 | N/A |
| Revenue Next Year | $28.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $3.65 |
| 52 Week High | $29.90 | $21.31 |
| Indicator | NEON | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 61.85 |
| Support Level | $1.27 | $3.91 |
| Resistance Level | $2.04 | $5.06 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 54.90 | 100.00 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.